NCT03776643View on ClinicalTrials.gov

Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions
Allergic Rhinoconjunctivitis to Birch PollenWith a Positive Skin Prick Test to Birch Pollen
Interventions
DRUG

ILT-101 ld-(IL2)

Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months

Trial Locations (2)

67000

Centre d'essais cliniques, ALYATEC, Strasbourg

75013

CIC Biothérapies - Service de Biothérapies, Paris

Sponsors

Collaborators (1)

Iltoo Pharma
All Listed Sponsors
collaborator

Iltoo Pharma

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER